[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanghai 6th People's Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":599},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,35,0,25,[9,41,69,94,117,140,161,179,201,228,253,280,307,331,364,385,407,427,447,468,484,512,538,556,579],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100642786","phase-1-a-multicenter-prospective-randomized-open-label-phase-ibii-study-of-celecoxib-plus-pembrolizumab-and-gemcitabinecisplatin-versus-pembrolizumab-and-gemcitabinecisplatin-in-patients-with-ck56-high-unresectable-locally-advanced-or-metastatic-intrahepatic-cholangiocarcinoma-100642786",false,"NCT07632235","A Multicenter, Prospective, Randomized, Open-label Phase Ib\u002FII Study of Celecoxib Plus Pembrolizumab and Gemcitabine\u002FCisplatin Versus Pembrolizumab and Gemcitabine\u002FCisplatin in Patients With CK5\u002F6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Histologically or cytologically confirmed intrahepatic cholangiocarcinoma (iCCA).\n* Unresectable locally advanced, recurrent, or metastatic disease.\n* No prior systemic therapy for advanced disease.\n* At least one measurable lesion according to RECIST v1.1.\n* ECOG performance status of 0-1.\n* Availability of adequate pre-treatment tumor tissue for central pathological review.\n* CK5\u002F6 H-score ≥ 1.0 as determined by central laboratory testing.\n* Adequate organ and bone marrow function as defined by protocol-specified laboratory criteria.\n* Patients with biliary obstruction must have undergone effective drainage and achieved clinical stabilization prior to enrollment.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Other primary malignancies including extrahepatic cholangiocarcinoma, gallbladder carcinoma, or ampullary carcinoma.\n* CK5\u002F6 H-score \\\u003C 1.0.\n* Prior systemic therapy for advanced or metastatic disease.\n* Active gastrointestinal bleeding, peptic ulcer disease, or high risk of gastrointestinal perforation.\n* Recent history of significant cardiovascular events including myocardial infarction, stroke, uncontrolled hypertension, or severe heart failure.\n* Known hypersensitivity to celecoxib, sulfonamides, NSAIDs, or aspirin-exacerbated respiratory disease.\n* Active autoimmune disease or conditions contraindicating pembrolizumab therapy.\n* Severe renal impairment.\n* Child-Pugh class C hepatic impairment.\n* Active uncontrolled infection.\n* Any condition that, in the investigator's opinion, would interfere with study participation or interpretation of results.","ALL","18 Years",{"count":19,"type":20},112,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This study aims to evaluate whether adding celecoxib to standard therapy can improve clinical outcomes in patients with advanced intrahepatic cholangiocarcinoma. The current standard treatment typically consists of immunotherapy combined with chemotherapy; however, there are significant inter-patient differences in treatment response. Therefore, this study further introduces the biomarker CK5\u002F6 to identify patient subgroups who are more likely to benefit, thereby exploring a more precise therapeutic strategy.\n\nAll eligible participants will be randomly assigned after enrollment to either the control group or the experimental group. The control group will receive the current standard first-line regimen, which includes the immunotherapy agent pembrolizumab combined with the chemotherapy agents gemcitabine and cisplatin. The experimental group will receive the same standard treatment, with the addition of oral anti-inflammatory therapy with celecoxib taken twice daily throughout the entire treatment period.\n\nEach treatment cycle lasts 21 days. During treatment, patients will undergo regular imaging assessments, laboratory tests, and safety evaluations to monitor tumor response and treatment-related adverse events, and will be followed until disease progression or discontinuation of treatment. In addition, blood and tissue samples will be collected during the study to investigate tumor biology and potential predictive biomarkers.\n\nThe primary endpoints of this study include progression-free survival and objective response rate, along with concurrent safety evaluation. Adverse events potentially associated with chemotherapy, immunotherapy, and celecoxib may occur, such as bone marrow suppression, gastrointestinal reactions, immune-related inflammatory responses, as well as renal or cardiovascular toxicities. The study team will closely monitor and promptly manage all adverse events.\n\nThis study aims to explore a CK5\u002F6-based stratified personalized combination therapy strategy, with the goal of improving treatment benefit in patients with advanced intrahepatic cholangiocarcinoma and providing evidence for optimizing future clinical treatment strategies.",[27],"Intrahepatic Cholangiocarcinoma (Icc)","RECRUITING","2026-06-22",{"date":31,"type":32},"2026-06-25","ACTUAL",{"date":34,"type":20},"2026-07-01",{"date":36,"type":20},"2030-12-31",{"name":38,"class":39},"Shanghai 6th People's Hospital","OTHER",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100624795","cgm-for-insulin-treated-t2dm-during-post-discharge-transition-100624795","NCT07414277","CGM for Insulin-Treated T2DM During Post-Discharge Transition","Effects of Continuous Glucose Monitoring on Patients With Type 2 Diabetes Treated With Insulin During Post-Discharge Transition: A Multicenter Randomized Controlled Trial","TRANSIT-CGM","Inclusion Criteria:\n\n1. Age 18 to 80 years (inclusive).\n2. Confirmed diagnosis of type 2 diabetes mellitus (T2DM).\n3. HbA1c between 8.0% and 13.0% (inclusive) within the last 1 month prior to screening\u002Fenrollment.\n4. Planned to receive insulin therapy for at least 6 months after hospital discharge, as assessed\u002Fconfirmed by the treating physician (principal physician).\n\nExclusion Criteria:\n\n1. Current use of a real-time continuous glucose monitoring (RT-CGM) device, or use within the 3 months prior to enrollment.\n2. Severe skin disease at the sensor insertion site, or allergy to adhesive tape\u002Fadhesives.\n3. Pregnant women; positive pregnancy test at screening; or planning pregnancy during the study period.\n4. Currently participating in, or planning to participate in, another clinical trial.\n5. Current use of oral corticosteroid therapy, or anticipated use during the trial period.\n6. Severe liver disease, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>3 times the upper limit of normal (ULN).\n7. Severe renal impairment or end-stage renal disease, defined as estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73 m².\n8. Any condition that, in the investigator's opinion, makes the participant unsuitable for the trial, for example: history of ocular trauma or other diagnosed eye diseases causing visual impairment; unwillingness to participate or inability to adequately understand\u002Fcomply due to speech\u002Flanguage impairment; or presence of psychiatric disorders.","80 Years",{"count":51,"type":20},160,[53],"NA","The transition from inpatient care to the home setting is a critical phase for glycemic management, often associated with decreased adherence and deterioration of glycemic control. This multicenter, randomized, open-label, controlled trial aims to evaluate the efficacy of Real-Time Continuous Glucose Monitoring (RT-CGM) versus Self-Monitoring of Blood Glucose (SMBG) in patients with Type 2 Diabetes Mellitus (T2DM) treated with insulin during the post-discharge transitional period.\n\nA total of 160 eligible participants will be randomized in a 1:1 ratio to either the RT-CGM group or the SMBG group. Participants will wear RT-CGM intermittently (every 4 weeks) or perform SMBG for the 12-week intervention period. They will also visit the clinic at Week 12 and Week 24 for follow-up assessments.",[56],"Type 2 Diabetes Mellitus (T2DM)",[58,59],"continuous glucose monitoring","insulin-treated","2026-06-21",{"date":62,"type":32},"2026-06-24",{"date":64,"type":32},"2026-05-11",{"date":66,"type":20},"2027-12-31",{"name":38,"class":39},4,{"id":70,"slug":71,"hasResults":12,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":75,"targetDuration":77,"studyType":78,"phases":4,"briefSummary":79,"conditions":80,"keywords":84,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":93,"locationsCount":40},"100577856","postoperative-pain-of-robotic-endoscopic-and-open-lateral-neck-dissection-100577856","NCT06803732","Postoperative Pain of Robotic, Endoscopic and Open Lateral Neck Dissection","Inclusion Criteria:\n\n* Patients underwent lateral neck dissection via robotic, endoscopic or open approach\n* Clinical diagnosis of differentiated thyroid cancer\n* Clinical diagnosis of metastatic lateral lymph nodes\n\nExclusion Criteria:\n\n* Participants with distant metastasis\n* Participants with history of neck surgery or radiation\n* Participants with vocal fold fixation by preoperative fibrolaryngoscope",{"count":76,"type":20},600,"6 Months","OBSERVATIONAL","Postoperative pain is a good indicator to confirm the advantages of the surgical methods in the era of minimally invasive surgery. Lateral neck dissection requires extensive dissection which may leads to postoperative numbness and pain. Robotic thyroid surgery has the advantage of precise and careful dissection and avoid the L-shape incision in the open approach. The study aims to explore the pain intensity and severity of lateral neck dissection on operation day, postoperative month 1 and postoperative month 3 among the robotic, endoscopic and open approach.",[81,82,83],"Pain, Postoperative","Thyroid Diseases","Surgery",[85,86,87],"Lateral neck dissection","Robotic thyroid surgery","Minimally invasive surgery","2026-06-20",{"date":62,"type":32},{"date":91,"type":32},"2024-11-01",{"date":66,"type":20},{"name":38,"class":39},{"id":95,"slug":96,"hasResults":12,"nctId":97,"briefTitle":98,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":100,"targetDuration":102,"studyType":78,"phases":4,"briefSummary":103,"conditions":104,"keywords":106,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":116,"locationsCount":40},"100579026","nomogram-for-predicting-difficult-laparoscopic-appendectomy-100579026","NCT06818942","Nomogram for Predicting Difficult Laparoscopic Appendectomy","Inclusion Criteria:\n\n* Clinical diagnosis of acute appendicitis\n* Participants who underwent laparoscopic appendectomy\n\nExclusion Criteria:\n\n* Participants refused or could not tolerate laparoscopic appendectomy\n* Incomplete preoperative examination or missed information",{"count":101,"type":20},500,"3 Months","No prior studies have stratified the difficulty of laparoscopic appendectomy (LA). The investigators aimed to investigate preoperative factors as indicators of difficult LAs based on the experience of surgical trainees and to develop a predictive model accordingly.",[105],"Emergencies",[107,108,109],"Laparoscopic appendectomy","Surgical difficulty","Training program","2026-05-02",{"date":112,"type":32},"2026-05-07",{"date":114,"type":32},"2025-01-26",{"date":66,"type":20},{"name":38,"class":39},{"id":118,"slug":119,"hasResults":12,"nctId":120,"briefTitle":121,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":123,"targetDuration":77,"studyType":78,"phases":4,"briefSummary":125,"conditions":126,"keywords":131,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":135,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":139,"locationsCount":40},"100572211","surgical-competency-for-robot-assisted-thyroidectomy-construction-and-validation-of-a-robotic-thyroidectomy-assessment-score-rtas-100572211","NCT06730321","Surgical Competency for Robot-Assisted Thyroidectomy: Construction and Validation of a Robotic Thyroidectomy Assessment Score (RTAS)","Inclusion Criteria:\n\n* Clinical diagnosis of differentiated thyroid cancer with a maximum diameter not exceeding 4 cm\n* Clinical diagnosis of benign thyroid nodules with a maximum diameter not exceeding 6 cm\n* Participants with high cosmetic expectations\n* Participants underwent robotic thyroidectomy without open conversion\n\nExclusion Criteria:\n\n* Participants with history of neck surgery or radiation\n* Participants with vocal fold fixation by preoperative fibrolaryngoscope\n* Participants with preoperative examination suggestive of distant invasion\n* Participants with fusion or fixed of lymph nodes in the neck",{"count":124,"type":20},200,"To develop and validate a structured scoring tool (robotic thyroidectomy assessment score, RTAS) for assessing and quantifying surgical performance in robotic thyroidectomy (RT).",[127,128,82,129,130],"Thyroid Cancer","Thyroid Nodule","Thyroid Cancer, Papillary","Thyroid Cancer, Follicular",[132,133,134],"Robotic thyroidectomy","Surgical competency","Robotic thyroidectomy assessment score",{"date":112,"type":32},{"date":137,"type":32},"2024-12-12",{"date":66,"type":20},{"name":38,"class":39},{"id":141,"slug":142,"hasResults":12,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":149,"conditions":150,"keywords":151,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":155,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":40},"100572870","renovated-prediction-model-for-difficult-transoral-and-submental-endoscopic-thyroidectomy-100572870","NCT06738888","Renovated Prediction Model for Difficult Transoral and Submental Endoscopic Thyroidectomy","Renovated Prediction Model for Difficult. Transoral and Submental Endoscopic Thyroidectomy","Inclusion Criteria:\n\n* Clinical diagnosis of differentiated thyroid cancer with a maximum diameter not exceeding 4 cm\n* Clinical diagnosis of benign thyroid nodule with a maximum diameter not exceeding 6 cm\n* Absence of suspicious lateral lymph nodes or distant metastases\n\nExclusion Criteria:\n\n* Participants with fusion or fixation of lymph nodes in the neck\n* Participants with history of neck surgery or radiation\n* Participants with vocal fold fixation by preoperative fibrolaryngoscope\n* Participants with preoperative examination suggestive of extrathyroidal invasion\n* Participants with a significantly restricted neck and\u002For jaw",{"count":148,"type":20},300,"The investigators have previously proposed a prediction model for difficult transoral and submental thyroidectomy through a retrospective study. In order to better promote transoral and submental endoscopic approach for thyroid surgery and to set up an appropriate training course, the investigators aim to renovate and validate the prediction model through a prospective study.",[127,82,128],[152,153,154],"Endoscopic thyroidectomy","Transoral and submental approach","Prediction model",{"date":112,"type":32},{"date":157,"type":32},"2024-05-01",{"date":159,"type":20},"2028-12-31",{"name":38,"class":39},{"id":162,"slug":163,"hasResults":12,"nctId":164,"briefTitle":165,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":168,"conditions":169,"keywords":171,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":174,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":178,"locationsCount":40},"100567668","nomogram-for-predicting-difficult-transoral-and-submental-thyroidectomy-100567668","NCT06671184","Nomogram for Predicting Difficult Transoral and Submental Thyroidectomy","Inclusion Criteria:\n\n* Clinical diagnosis of differentiated thyroid cancer with a maximum diameter not exceeding 4 cm\n* Absence of suspicious lateral lymph nodes or distant metastases\n* Participants with high cosmetic expectations\n* Participants who underwent total thyroidectomy and central lymph node dissection.\n\nExclusion Criteria:\n\n* Participants with fusion or fixation of lymph nodes in the neck\n* Participants with history of neck surgery or radiation\n* Participants with vocal fold fixation by preoperative fibrolaryngoscope\n* Participants with preoperative examination suggestive of extrathyroidal invasion\n* Participants with a significantly restricted neck",{"count":101,"type":20},"No prior studies have stratified the difficulty of transoral and submental thyroidectomy (TOaST). The investigators aimed to investigate preoperative factors as indicators of difficult TOaSTs and to develop a predictive model accordingly.",[170],"Differentiated Thyroid Cancer",[172,173,108],"Differentiated thyroid cancer","Transoral and submental thyroidectomy",{"date":112,"type":32},{"date":176,"type":32},"2021-01-01",{"date":66,"type":20},{"name":38,"class":39},{"id":180,"slug":181,"hasResults":12,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":186,"enrollmentInfo":187,"targetDuration":4,"studyType":21,"phases":188,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":40},"100630070","phase-4-an-exploratory-study-on-efficacy-and-safety-of-fosaprepitant-and-palonosetron-hydrochloride-for-injection-in-preventing-cinv-from-multi-agent-hec-100630070","NCT07482891","An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC","An Exploratory Study on the Efficacy and Safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in Preventing Nausea and Vomiting Caused by Highly Emetogenic Multi-Agent Chemotherapy","Inclusion Criteria:\n\n* Aged 18-75 years, any gender, voluntarily signed informed consent form (ICF), with good compliance;\n* Histologically or cytologically confirmed malignant solid tumour;\n* No prior exposure to any chemotherapeutic agents;\n* First-time participants with malignant solid tumours scheduled to receive a treatment regimen based on multi-day HEC chemotherapy (HEC refers to the risk of anti-tumour drug-induced nausea and vomiting as defined in the 2023 Edition of the Chinese Guidelines for the Prevention and Treatment of Nausea and Vomiting Associated with Anti-tumour Therapy; 'multi-day' denotes each chemotherapy cycle lasting at least 3 days);\n* No impairment in speech, hearing, or comprehension;\n* Expected survival ≥ 3 months;\n* ECOG : 0-1;\n* Organ function must be adequate and meet the following criteria:\n\n  1. Neutrophil count ≥ 1.5 × 10⁹\u002FL;\n  2. Haemoglobin ≥ 90 g\u002FL;\n  3. Platelet count ≥ 100 × 10⁹\u002FL;\n  4. Total bilirubin ≤ 1.5 × upper limit of normal (ULN);\n  5. In patients without known liver metastases, aspartate aminotransferase ≤ 2.5 × ULN and\u002For alanine aminotransferase ≤ 2.5 × ULN (for patients with liver metastases, may be relaxed to ≤ 5 × ULN);\n  6. Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 50 ml\u002Fmin;\n  7. Electrocardiogram: QTc ≤ 450 ms (males), QTc ≤ 470 ms (females);\n  8. Echocardiogram: LVEF (left ventricular ejection fraction) ≥ 50%.\n* Female subjects of childbearing potential, and male subjects with female partners of childbearing potential, must use one form of effective contraception from the time of signing the informed consent form until 6 months after the last dose (see Appendix). Female subjects of childbearing potential must have a negative blood pregnancy test within 72 hours prior to enrolment and must not be breastfeeding.\n\nExclusion Criteria:\n\n* Subjects with symptomatic brain metastases or any symptoms suggestive of brain metastases or intracranial hypertension;\n* Subjects who have received radiotherapy within 7 days prior to enrolment, extensive radiotherapy (e.g., whole-chest or whole-abdomen radiotherapy) within 3 months prior to enrolment, local palliative radiotherapy (e.g., for bone or lymph node metastases) within 1 month prior to enrolment, or who are scheduled to undergo any radiotherapy during the study period;\n* Administration within 2 days prior to enrolment of medications with potential antiemetic effects: first-generation 5-HT3 receptor antagonists (e.g., ondansetron), phenothiazines (e.g., prochlorperazine), butyrophenones (e.g., haloperidol), benzamides (e.g., metoclopramide), domperidone, cannabinoids, traditional Chinese medicines with potential antiemetic effects, scopolamine, or secloperazine;\n* Initiation of benzodiazepine or opioid therapy within 2 days prior to enrolment (excluding zolpidem, temazepam, or midazolam administered alone daily);\n* Subjects who commenced morphine use within 7 days prior to enrolment (excluding those on stable doses);\n* Systemic corticosteroid therapy (including but not limited to dexamethasone, hydrocortisone, methylprednisolone, or prednisolone) or sedating antihistamines (e.g., diphenhydramine) administered within 7 days prior to enrolment (Note: Single-dose steroids for contrast allergy prophylaxis, or topical\u002Finhaled administration are permitted);\n* Use of palonosetron within 14 days prior to enrolment;\n* Use of NK-1 receptor antagonists within 28 days prior to enrolment;\n* Vomiting and\u002For retching, nausea occurring within 24 hours prior to enrolment;\n* Presence of poorly controlled serosal effusions, including pleural effusion, ascites, pericardial effusion (exclusion may be waived if controlled by treatment and stable for ≥2 weeks);\n* Severe cardiovascular disease within 3 months prior to enrolment, including but not limited to acute myocardial infarction, unstable angina pectoris, significant valvular or pericardial disease, history of ventricular tachycardia, symptomatic chronic heart failure (New York Heart Association \\[NYHA\\] Class II to IV), or history of severe cardiac conduction abnormalities (e.g., torsades de pointes ventricular tachycardia);\n* Concurrent active hepatitis B (HBV DNA ≥ 2000 IU\u002FmL or 10⁴ copies\u002FmL), active hepatitis C (HCV-Ab positive with HCV-RNA ≥ ULN), known acquired immunodeficiency syndrome (AIDS) or HIV-positive status, or syphilis-positive status;\n* Concurrent conditions precluding dexamethasone administration, such as active infections (e.g., pneumonia) or uncontrolled conditions (e.g., diabetic ketoacidosis, intestinal obstruction);\n* Known contraindications and\u002For allergies to study medications;\n* Participation in another clinical trial within 30 days prior to enrolment (as determined by the use of study medication);\n* Subjects deemed by the investigator to have other conditions rendering them unsuitable for this study.","75 Years",{"count":124,"type":20},[189],"PHASE4","This prospective, multicenter, non-comparative, open-label trial design aims to evaluate the efficacy and safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in preventing nausea and vomiting induced by hyperemetic chemotherapy (HEC) over multiple days. Eligible subjects were screened and assigned to Arm 1 or Arm 2 according to medical protocol. Arm 1: Fosrolapitant and Palonosetron Hydrochloride for Injection + Dexamethasone + Olanzapine; Arm 2: Fosrolapitant and Palonosetron Hydrochloride for Injection + Dexamethasone. Study drug administration commenced within 48 hours post-randomization, with follow-up visits and examinations completed as per protocol.",[192],"Chemotherapy-induced Nausea and Vomiting","2026-04-29",{"date":195,"type":32},"2026-04-30",{"date":197,"type":32},"2026-03-10",{"date":199,"type":20},"2026-12-31",{"name":38,"class":39},{"id":202,"slug":203,"hasResults":12,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":208,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":209,"targetDuration":77,"studyType":78,"phases":4,"briefSummary":211,"conditions":212,"keywords":215,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":227},"100589745","neural-mechanism-of-cerebrocardiac-syndrome-following-traumatic-brain-injury-100589745","NCT06958406","Neural Mechanism of Cerebrocardiac Syndrome Following Traumatic Brain Injury","Lesion-Network Mapping Analysis With Brain Connectomics to Reveal the Neural Mechanisms of Cerebrocardiac Syndrome Following Traumatic Brain Injury","Inclusion Criteria:\n\n* Patients with isolated closed head trauma\n* Age 18-80 years old\n* Admitted to hospital within 24 hours of injury\n* Mild or moderate TBI (Glasgow Coma Scale score of 9-15)\n* Signed consent form\n\nExclusion Criteria:\n\n* Severe TBI (Glasgow Coma Scale score of 3-8)\n* A history of stroke, TBI, intracranial tumor or surgery in the past 1 year\n* A history of coronary heart disease, structural heart disease and other primary heart diseases or suspected cardiac symptoms prior to injury\n* Causes of abnormal cardiac biomarkers such as renal insufficiency, severe anemia, sepsis, cardiotoxic drugs and so on\n* Not suitable for MRI examinations, such as pregnant women and those with metal implants in the body\n* Undergo surgery prior to MRI examinations or cardiac testing",true,{"count":210,"type":20},90,"Cerebrocardiac syndrome (CCS), including myocardial injury, arrhythmia or heart failure is one of serious complications of traumatic brain injury (TBI), mostly occurs within seven days after TBI, which directly aggravates the brain damage and affects the prognosis of TBI patients. Accumulative evidences suggest that autonomic nervous system disorder is a key initiation point for CCS, but how TBI affects the specific action patterns is not yet clear. Therefore, elucidating the neural mechanisms of TBI-induced CCS, maintaining the central sympathetic-parasympathetic balance through novel interventions such as noninvasive brain stimulation, may fundamentally block the downstream peripheral mechanism, thus achieving effective prevention and treatment for CCS. Based on the current emerging research in brain connectomics and lesion-symptom mapping, we speculate that cerebral contusions can cause structural or functional disconnection of key nodes in the central autonomic nervous system regulatory network, thereby mediating the occurrence of TBI-induced CCS.\n\nIn this study, magnetic resonance imaging (MRI) or functional MRI (fMRI) examinations were performed in patients with mild or moderate TBI with aim to explore the association between structural and functional disconnection caused by cerebral contusion and TBI-induced CCS, and to screen out the neural anatomical structures to predict CCS following TBI, providing therapy targets for prevention and treatment of CCS.",[213,214],"Traumatic Brain Injury","Cerebrocardiac Syndrome",[216,217,218],"traumatic brain injury","cerebrocardiac syndrome","brain connectomics","2026-04-22",{"date":221,"type":32},"2026-04-23",{"date":223,"type":32},"2025-08-10",{"date":225,"type":20},"2027-07-31",{"name":38,"class":39},2,{"id":229,"slug":230,"hasResults":12,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":208,"sex":16,"minAge":17,"maxAge":235,"enrollmentInfo":236,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":238,"conditions":239,"keywords":242,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":248,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":252,"locationsCount":227},"100447945","correlation-between-intestinal-microecology-imbalance-and-stroke-in-young-adults-100447945","NCT05113043","Correlation Between Intestinal Microecology Imbalance and Stroke in Young Adults","Research on Correlation Between Intestinal Microecology Imbalance and the Risk and Prognosis of Stroke in Young Adults","Inclusion Criteria:\n\n* Clinical diagnosis of acute ischemic or hemorrhagic stroke\n* Admission within 12 hours\n* Aged 18-45 years\n\nExclusion Criteria:\n\n* History of neurological diseases, myocardial infarction, renal and hepatic abnormalities and metabolic diseases\n* Combined with tumors, inflammatory bowel disease and other digestive system diseases\n* Combined with serious life-threatening diseases or condition\n* Any antibiotics, probiotics or prebiotic treatment within 3 months\n* Deteriorate and die before collecting faecal samples","45 Years",{"count":237,"type":20},60,"The relationship between the intestinal microecology and stroke has become a research hotspot in neurology field today. Maintaining the balance of the intestinal microbiota are expected to bring new breakthroughs for prevention and treatment of stroke. In recent years, stroke in young adults has an increasing incidence and a considerable socioeconomic impact because of high disability rate and health-care costs. So there is an urgent need to explore the role and mechanism of intestinal microecology imbalance in stroke, especially in the development and prognosis of stroke in young people. This study aims to use multi-omics technologies, including microbial diversity, metagenomics and metabonomics, to reveal the characteristics of intestinal flora in young stroke patients, identify biomarkers for predicting outcome after stroke and early detection of young people at high risk of stroke, and to further explore the role of gut-brain axis in the pathogenesis of stroke.",[240,241],"Ischemic Stroke","Hemorrhagic Stroke",[243,244,245,246,247],"ischemic stroke","hemorrhagic stroke","intestinal microecology","multi-omics analysis","prognosis",{"date":221,"type":32},{"date":250,"type":32},"2022-02-01",{"date":66,"type":20},{"name":38,"class":39},{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":259,"eligibilityCriteria":260,"healthyVolunteers":12,"sex":16,"minAge":261,"maxAge":4,"enrollmentInfo":262,"targetDuration":4,"studyType":21,"phases":264,"briefSummary":265,"conditions":266,"keywords":268,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":279},"100593533","effect-of-continuous-glucose-monitoring-system-on-glycemic-control-in-non-insulin-treated-elderly-people-with-type-2-diabetes-100593533","NCT07007676","Effect of Continuous Glucose Monitoring System on Glycemic Control in Non-insulin-Treated Elderly People With Type 2 Diabetes","Effect of contINuous Glucose moniToring System on glycEmic controL in Non-insuLin-Treated Elderly People With Type 2 Diabetes: a Randomized Controlled Trial","INTELLECT","Inclusion Criteria:\n\n* Age ≥ 60 years at the time of screening;\n* Diagnosed with type 2 diabetes mellitus;\n* Treated with two or more oral antidiabetic drugs with a stable medication regimen (medication classes) during the 3 months prior to entry;\n* Suboptimal glycemic control, defined as HbA1c ≥ 7.5% and ≤ 10% at screening or within 30 days prior to screening visit;\n* Has a smart phone compatible with CGM and BGM systems;\n* Willing and able to provide written informed consent;\n* At least 240 hours (10 out of 14 days) of sensor glucose data from the blinded CGM pre-randomization phase.\n\nExclusion Criteria:\n\n* Use of insulin or Glucagon-Like Peptide-1 （GLP-1） receptor agonists within 3 months prior to screening;\n* Use of any CGM device within 3 months prior to screening;\n* Participants were unable to tolerate tape adhesive around sensor placement area, or with medically documented allergy towards the adhesive (glue) of plasters, or with serious skin diseases (e.g. psoriasis vulgaris, bacterial skin diseases) around sensor placement area;\n* Considered unsuitable for participation by the investigators, including but not limited to individuals with dementia, psychiatric disorders, extreme visual or hearing impairment that would impair ability to use real-time CGM assessed;\n* Planned surgery or other procedures within the next 6 months that may interfere with scheduled follow-up visits;\n* Current or anticipated acute uses of glucocorticoids (oral, injectable, or IV), that will affect glycemic control;\n* Estimated glomerular filtration rate (eGFR) \\\u003C 30 ml\u002Fmin\u002F1.73m2;\n* Participation in any other clinical trial within 3 month prior to screening, or concurrently enrolled, or planning to participate in another trial during the study period.","60 Years",{"count":263,"type":20},148,[53],"The goal of this clinical trial is to learn if continuous glucose monitoring system works to improve glucose control in non-insulin-treated older adults with type 2 diabetes. The main questions it aims to answer are:\n\n* Dose the use of continuous glucose monitoring system improve glucose control in older adults with type 2 diabetes treated with oral antidiabetic drugs only?\n* Dose the use of continuous glucose monitoring system affect psychological outcomes in older adults with type 2 diabetes treated with oral antidiabetic drugs only? Researchers will compare continuous glucose monitoring to standard blood glucose monitoring to see if continuous glucose monitoring works better in glucose management.\n\nParticipants will:\n\n* Wear continuous glucose monitoring every 2 months or standard blood glucose monitoring for 6 months\n* Visit the clinic once every 2 months for follow-up\n* Keep a diary of their blood glucose when continuous glucose monitoring was not used",[267],"Diabetes Mellitus Type 2",[58,269,270],"non-insulin-treated","type 2 diabetes in the elderly","2026-04-08",{"date":273,"type":32},"2026-04-13",{"date":275,"type":32},"2025-07-14",{"date":277,"type":20},"2027-06-30",{"name":38,"class":39},15,{"id":281,"slug":282,"hasResults":12,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":12,"sex":16,"minAge":288,"maxAge":289,"enrollmentInfo":290,"targetDuration":4,"studyType":21,"phases":292,"briefSummary":293,"conditions":294,"keywords":296,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":40},"100620548","phase-2-magnate-s-paclitaxel-polymer-micelles-combo-in-advanced-sarcoma-100620548","NCT07359053","MAGNATE-S: Paclitaxel Polymer Micelles Combo in Advanced Sarcoma","MAGNATE-S: A Phase 2 Exploratory Study of Paclitaxel Polymer Micelles Combined With Gemcitabine and Anti-Angiogenic TKIs (Lenvatinib or Anlotinib) for Advanced Bone and Soft Tissue Sarcomas","MAGNATE-S","Inclusion Criteria:\n\n* Informed Consent: The subject has signed the informed consent form after receiving and understanding full explanation regarding the trial's purpose, procedures, anticipated efficacy, pharmacological actions, and risks.\n* Target Population:\n\n  1. Histologically confirmed advanced\u002Fmetastatic bone or soft tissue sarcoma. (If recurrence or metastasis is not definitive, a biopsy with frozen section is recommended. Enrollment may proceed if frozen pathology suggests recurrence\u002Fmetastasis.)\n  2. At least one measurable lesion per RECIST 1.1 criteria.\n  3. Disease progression after prior first-line standard chemotherapy; ECOG performance status 0-2.\n  4. Life expectancy ≥ 3 months.\n  5. Willing and able to comply with study procedures, treatment, and follow-up.\n  6. No contraindications to paclitaxel polymer micelles, gemcitabine, or small-molecule anti-angiogenic targeted agents.\n* Physical Examination and Laboratory Results:\n\n  1. Adequate hematologic function: i) Absolute neutrophil count (ANC) ≥ 1.8 × 10⁹\u002FL; ii) Platelet count ≥ 100 × 10⁹\u002FL; iii) Hemoglobin ≥ 90 g\u002FL. (If transfusions are given during screening, a repeat test after 1 week must meet these criteria.)\n  2. Adequate hepatic function: i) Total bilirubin ≤ 1.5 × upper limit of normal (ULN); ii) AST and ALT ≤ 2.5 × ULN (≤ 5 × ULN if liver metastases are present); Alkaline phosphatase (ALP) ≤ 5 × ULN (liver mets) or ≤ 10 × ULN (bone mets).\n  3. Adequate renal function: Serum creatinine ≤ 1.5 × ULN or calculated creatinine clearance ≥ 50 mL\u002Fmin.\n  4. Adequate coagulation: INR ≤ 1.5 × ULN and PT\u002FaPTT ≤ 1.5 × ULN, unless on stable anticoagulant therapy.\n* Hepatitis B: Subjects positive for HBsAg are eligible if, in the investigator's judgment, their chronic hepatitis B is stable and does not increase the subject's risk.\n* Cardiac Function: No symptomatic cardiac insufficiency at baseline (NYHA class ≤ II) and no clinically significant ECG abnormalities.\n* Age and Reproductive Status:\n\n  1. Aged 12-70 years (male and female).\n  2. Subjects of childbearing potential must agree to use effective contraception during the trial. A negative serum or urine pregnancy test within 24 hours before chemotherapy is required for women of childbearing potential.\n  3. Female subjects must not be breastfeeding.\n\nExclusion Criteria:\n\n* Known allergy or intolerance to any component or excipient of the investigational products.\n* Primary brain tumor or central nervous system (CNS) metastases (including leptomeningeal metastases), except for a single, well-controlled, asymptomatic brain metastasis. CNS tumors still presenting with increased intracranial pressure or neuropsychiatric symptoms after treatment.\n* Uncontrolled acute or chronic infections, or other severe concurrent medical conditions.\n* History of other malignancies within the past 5 years, except for cured basal cell carcinoma of the skin or carcinoma in situ of the cervix.\n* Active hepatitis or hepatic tumor burden exceeding 50% of the total liver volume.\n* Uncontrolled third-space fluid accumulation not manageable by drainage (e.g., moderate to large pleural effusion, pericardial effusion, or ascites). Minimal asymptomatic fluid not requiring intervention may be allowed upon strict review.\n* Psychiatric illness or cognitive impairment leading to poor compliance or inability to cooperate and report treatment responses.\n* Severe organic disease or major organ failure (e.g., decompensated heart or lung failure) precluding tolerance to chemotherapy.\n* Coagulopathy (INR \\>1.5, APTT \\>1.5 × ULN), bleeding tendency (e.g., active gastric ulcer, stool occult blood \\[++\\], hematemesis and\u002For melena within the past 3 months, hemoptysis), or tumor proximity to major blood vessels.\n* Coronary artery disease above grade I, arrhythmia (including QTc interval \\>450 ms for males, \\>470 ms for females), use of antiarrhythmic medication, or relevant underlying cardiac disease\u002Fcardiac insufficiency.\n* Renal insufficiency, history of renal disease, or proteinuria (urine protein ≥2+ or 24-hour urine protein \\>1.0 g).\n* History of organ transplantation.\n* History of substance abuse, chronic alcoholism, or infectious diseases such as AIDS.\n* Long-term use of corticosteroids or immunosuppressants.\n* Vaccination with live or attenuated vaccines (e.g., measles, mumps, rubella, varicella, yellow fever, rabies, BCG, oral typhoid) within 4 weeks prior to enrollment, or planned vaccination during the study. COVID-19 vaccination is permitted.\n* Active hepatitis B (HBV DNA ≥1×10⁴ copies\u002FmL or ≥2000 IU\u002FmL) or hepatitis C (HCV RNA ≥15 IU\u002FmL) infection; positive HIV antibody (unless clinically indicated); or positive syphilis antibody (TPPA).\n* Any other condition deemed by the investigator to prevent completion of the trial or render the subject unsuitable (e.g., tumors like GIST or ALK-mutant inflammatory myofibroblastic tumor unsuitable for this chemotherapy regimen).","12 Years","70 Years",{"count":291,"type":20},46,[24],"What is this study about? This is a medical research study testing a new drug combination (\"Paclitaxel Polymer Micelles\" + \"Gemcitabine\" + \"Targeted Therapy\") for patients with locally advanced unresectable or metastatic bone and soft tissue sarcomas whose disease has progressed after first-line standard therapy. Currently, there is a lack of highly effective subsequent treatment options for these patients.\n\nWhy is this study being done? To improve efficacy: the investigators hope this drug combination can control tumor growth more effectively than current treatments.\n\nTo reduce toxicity: The \"Paclitaxel Polymer Micelles\" used in the study is a new formulation that may be safer than traditional paclitaxel, with a lower risk of severe allergic reactions.\n\nFor precise treatment: the investigators will select different targeted drugs (Lenvatinib for bone sarcoma or Anlotinib for soft tissue sarcoma) based on the tumor type, aiming for more tailored therapy.\n\nHow will the study be conducted?\n\nDesign: This is an exploratory study, planning to enroll approximately 46 patients in total, divided into two separate groups (23 for bone sarcoma, 23 for soft tissue sarcoma).\n\nProcess: Eligible and consenting patients will receive periodic combined drug therapy. Doctors will regularly evaluate efficacy and monitor safety through blood tests, US, CT, or MRI scans.\n\nPrimary Goal: The main focus is to see how many patients experience significant tumor shrinkage (Objective Response Rate), and to record all adverse reactions that occur.\n\nBiomarker Research: To better understand treatment mechanisms and identify potential predictive markers, this study includes the collection of biological samples for future research, with careful design to minimize additional burden. Small extra blood samples will be collected during scheduled routine blood draws required for clinical monitoring. If a tumor biopsy or surgery is performed as part of necessary clinical care, the investigators will request permission to preserve a portion of the remaining tissue that would otherwise be discarded. These samples may be analyzed using techniques such as genetic or protein testing.\n\nWhat does this mean for participants?\n\nPotential Benefits: Participants have the opportunity to receive the new drug \"Paclitaxel Polymer Micelles\" free of charge and may benefit from it. Their participation will provide valuable treatment experience for all future patients with similar conditions.\n\nPotential Risks: The drug combination may increase the risk of certain side effects, such as fatigue, nausea, high blood pressure, hand-foot skin reactions, or decreased blood cell counts. The research team has developed detailed plans to prevent and manage these situations.\n\nVoluntary Principle: Participation is completely voluntary. Patients have the right to withdraw from the study at any time, for any reason, without affecting their right to receive other routine medical care.\n\nIn summary, this study explores a regimen combining a novel nano-drug, chemotherapy, and precise targeted therapy, aiming to find a more effective and safer treatment option for patients with advanced bone and soft tissue sarcomas who have failed first-line treatment.",[295],"Sarcoma",[297,298],"advanced sarcoma","Paclitaxel Polymer Micelles","2026-01-13",{"date":301,"type":32},"2026-01-22",{"date":303,"type":20},"2025-12-25",{"date":305,"type":20},"2028-09-30",{"name":38,"class":39},{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":314,"targetDuration":77,"studyType":78,"phases":4,"briefSummary":316,"conditions":317,"keywords":320,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":329,"leadSponsor":330,"locationsCount":40},"100577855","public-perceptions-toward-robotic-surgery-telesurgery-and-telemedicine-100577855","NCT06803719","Public Perceptions Toward Robotic Surgery, Telesurgery and Telemedicine","Public Awareness, Trust, and Risk Perception Toward Robotic Surgery, Telesurgery and Telemedicine","Inclusion Criteria:\n\n* Chinese citizens aged 18 years or older\n* Able to understand and complete the questionnaire\n* Voluntarily participating in this study and providing informed consent\n\nExclusion Criteria:\n\n* Aged below 18 years\n* Unable to understand the questionnaire or unable to complete the questionnaire independently\n* Those who submit the questionnaire repeatedly",{"count":315,"type":20},1000,"This study aims to systematically assess the public's and clinicians' levels of awareness, attitudes, risk perception, acceptance, and potential concerns regarding robotic surgery and telesurgery. It also analyzes the key factors influencing their attitudes and explores the needs of physicians regarding training systems for robotic and telesurgery, as well as the factors affecting their preparedness.",[318,319],"Robotic Surgery","Telemedicine",[321,322,323,324],"Public perception","Telemedicine adoption","Surgical training","Surgical decision-making","2025-12-31",{"date":327,"type":32},"2026-01-02",{"date":91,"type":32},{"date":66,"type":20},{"name":38,"class":39},{"id":332,"slug":333,"hasResults":12,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":289,"enrollmentInfo":338,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":340,"conditions":341,"keywords":344,"overallStatus":355,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":4},"100615112","the-cgm-ogtt-glycemic-homeostasis-study-100615112","NCT07288372","The CGM-OGTT Glycemic Homeostasis Study","An Exploratory Investigation Into the Mechanism of Glycemic Homeostasis Regulation Under the Synergistic Conditions of Continuous Glucose Monitoring (CGM) and Oral Glucose Tolerance Test (OGTT)","Inclusion Criteria:\n\nTo be eligible to participate in this study, an individual must meet ALL of the following criteria:\n\n* Is aged between 18 and 70 years, inclusive.\n* And meets at least ONE of the following conditions:\n\n  * Presents with diabetes-related clinical symptoms or signs (e.g., unexplained ·polydipsia, polyphagia, polyuria, weight loss) and has been advised by a ·clinician to undergo an OGTT for diagnostic clarification.\n  * Has indicators of abnormal glucose metabolism:Impaired Fasting Glucose (IFG): Fasting venous plasma glucose ≥ 6.1 mmol\u002FL and \\\u003C 7.0 mmol\u002FL.and\u002For Glycated hemoglobin (HbA1c) in the pre-diabetes range of 5.7% to 6.4%.\n  * Has at least one of the following diabetes risk factors:Body Mass Index (BMI) ≥ 24 kg\u002Fm²；Has a first-degree relative (parent, sibling, or child) with a history of diabetes；Has a history of hypertension (or undergoing antihypertensive treatment) or dyslipidemia.\n\nExclusion Criteria:\n\n* An individual who meets ANY of the following criteria will be excluded from participation in this study:\n* Previously diagnosed with diabetes.\n* Use of medications that significantly affect glucose metabolism or gastrointestinal hormones (e.g., GLP-1 receptor agonists, DPP-4 inhibitors, glucocorticoids) within a specified washout period prior to enrollment.\n* History of gastrointestinal surgery (e.g., gastrectomy) or chronic pancreatic disease.\n* Presence of severe hepatic or renal impairment (e.g., ALT \\> 3 times the upper limit of normal, or eGFR \\\u003C 45 mL\u002Fmin\u002F1.73m²).\n* Pregnant or lactating women, or women planning to become pregnant during the study period.\n* Known allergy to soy (as the standardized meal may contain soy-based components).",{"count":339,"type":20},225,"This is a prospective, exploratory, observational study aimed at investigating the mechanisms of glycemic homeostasis by comparing continuous glucose monitoring (CGM) data with results from the oral glucose tolerance test (OGTT).\n\nThe study plans to enroll approximately 225 participants aged 18-70 years who are at risk for or suspected of having glucose metabolism disorders, but without a prior diagnosis of diabetes. Participants will be equipped with a blinded CGM device for 10-14 days. During this period, they will perform two standardized mixed-meal tolerance tests (MMTT) at home. Subsequently, they will undergo a standard 75g OGTT at the hospital, where blood samples will be collected at multiple time points to measure glucose, insulin, C-peptide, and gastrointestinal hormones (GLP-1, GIP).\n\nBased on the 2-hour blood glucose value from the OGTT, participants will be naturally categorized into three groups for comparative analysis: Normal Glucose Tolerance (NGT), Pre-diabetes (Pre-DM), and Newly Diagnosed Type 2 Diabetes (T2DM).\n\nThe primary objective is to establish a quantitative relationship between CGM-derived parameters (e.g., glycemic variability, time-in-range) after the MMTT and the OGTT diagnostic results. Secondary objectives include assessing the feasibility and correlation between home-based MMTT and standard OGTT, exploring the impact of gastrointestinal hormone responses on daily glucose fluctuations, and investigating the association between postprandial glucose dynamics and vascular reactivity (e.g., postprandial hypotension).",[342,343],"Type 2 Diabetes","Glucose Metabolism Disorders",[345,346,347,348,349,350,351,352,353,354],"Continuous Glucose Monitoring","CGM","Oral Glucose Tolerance Test","OGTT","Mixed-Meal Tolerance Test","Glycemic Variability","Incretins","Home-Based Testing","GLP-1","GIP","NOT_YET_RECRUITING","2025-12-21",{"date":358,"type":32},"2025-12-23",{"date":360,"type":20},"2025-12-18",{"date":362,"type":20},"2027-08-10",{"name":38,"class":39},{"id":365,"slug":366,"hasResults":12,"nctId":367,"briefTitle":368,"officialTitle":369,"acronym":4,"eligibilityCriteria":370,"healthyVolunteers":12,"sex":371,"minAge":17,"maxAge":372,"enrollmentInfo":373,"targetDuration":4,"studyType":21,"phases":375,"briefSummary":376,"conditions":377,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":379,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":40},"100582440","glucose-pattern-in-infertile-women-receiving-assisted-reproduction-using-continuous-glucose-monitoring-100582440","NCT06863337","Glucose Pattern in Infertile Women Receiving Assisted Reproduction Using Continuous Glucose Monitoring","Glucose Pattern in Infertile Women Receiving Assisted Reproduction: a Prospective Study Using Continuous Glucose Monitoring","Inclusion Criteria:\n\n1. Informed consent and voluntary participation in this study;\n2. Age ≥ 18 years and ≤40 years old;\n3. Infertile patients who will undergo their first or second cycle of in vitro fertilization\u002Fintracytoplasmic sperm injection (IVF\u002FICSI) at the study center;\n4. The chosen ovulation promotion regimens is the GnRH antagonist regimen\u002Fprogesterone-promoting ovulation under hyperprogesterone state (PPOS) regimen.\n\nExclusion Criteria:\n\n1. Recent infections (excluding viral infections of the reproductive system such as HPV);\n2. Recent glucocorticoid treatment or chemotherapy;\n3. Clinical conditions affecting the outcome of assisted reproduction, including repeated implantation failure, recurrent spontaneous abortion, history of unilateral oophorectomy, uterine malformations, and parental karyotype abnormalities;\n4. Participants were unable to tolerate tape adhesive around sensor placement area, or with medically documented allergy towards the adhesive (glue) of plasters, or with serious skin diseases (e.g. psoriasis vulgaris, bacterial skin diseases) around sensor placement area.","FEMALE","40 Years",{"count":374,"type":20},100,[53],"No studies have been seen on glucose variation during medication for assisted reproduction. The aim of this study is to continuously observe glucose variation during assisted reproduction treatment using continuous glucose monitoring (CGM), and to further explore whether glucose variation will affect the outcomes related to assisted reproduction.",[378],"Infertility Female",{"date":358,"type":32},{"date":381,"type":32},"2025-03-26",{"date":383,"type":20},"2027-04-30",{"name":38,"class":39},{"id":386,"slug":387,"hasResults":12,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":4,"eligibilityCriteria":391,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":186,"enrollmentInfo":392,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":394,"conditions":395,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":227},"100589682","a-deep-learning-model-for-blood-volume-estimation-from-multi-modal-ultrasound-100589682","NCT06957587","A Deep Learning Model for Blood Volume Estimation From Multi-modal Ultrasound","Quantitative Estimation of Preoperative Blood Volume Using Multi-modal Ultrasound and Deep Learning","Inclusion Criteria:\n\n* Agree to join this study and sign the informed consent form;\n* Age between 18 and 75 years old (inclusive);\n* BMI (body mass index) is between 18 and 30 kg\u002Fm2;\n* American Society of Anesthesiologists (ASA) grades I-II\n\nExclusion Criteria:\n\n* Preoperative hemoglobin (Hb) \\\u003C10g\u002Fdl\n* Cardiac dysfunction (NYHA class III-IV), respiratory dysfunction (ATS class 2-4), history of liver and kidney dysfunction (such as transaminase \u002F albumin \u002F bilirubin abnormalities, hepatitis history, serum creatinine \u002F urea nitrogen rise, etc.), nervous system abnormalities (those who cannot cooperate due to stroke or its sequelae, Alzheimer, etc.);\n* The ultrasonic display of inferior vena cava, internal jugular vein, subclavian vein or common carotid artery is extremely poor, venous thrombosis or anatomical abnormalities;\n* Multiple injury with chest, abdomen or brain;\n* Pregnant woman",{"count":393,"type":20},800,"1. Background \\& Rationale:\n\n   Accurate assessment of a patient's blood volume (BV) status before surgery is critical for preventing perioperative complications. However, there is currently no clinically feasible, accurate, and non-invasive method for direct BV quantification. We hypothesize that dynamic ultrasound videos of major blood vessels contain rich, sub-visual spatiotemporal information about vascular compliance and filling that can be leveraged to estimate BV.\n2. Objective:\n\n   To develop and validate a deep learning model that integrates multi-modal ultrasound video data to achieve non-invasive, quantitative estimation of preoperative blood volume.\n3. Study Design:\n\n   A prospective, single-center, observational study.\n4. Methods:\n\n   Participants: Adult patients scheduled for surgery.\n\n   Data Acquisition:\n\n   Input (Features): Preoperative ultrasound video clips will be recorded in standardized views of four key vessels: the Internal Jugular Vein (IJV), Subclavian Vein (SCV), Inferior Vena Cava (IVC), and Common Carotid Artery (CA).\n\n   Target (Label): The true Blood Volume (BV) will be calculated for each patient using the acute normovolemic hemodilution (ANH) method. The change in hemoglobin concentration before and after this process is used to calculate the total blood volume with high clinical reliability.\n\n   Model Development: A hybrid deep learning architecture (e.g., CNN + LSTM\u002FTransformer) will be trained to extract features from the ultrasound videos and learn the complex, non-linear mapping to the BV value derived from ANH. The model will be trained and internally validated using a k-fold cross-validation approach.\n5. Expected Outcome \\& Significance:\n\nWe anticipate the development of a novel, end-to-end deep learning model capable of providing a quantitative BV estimate from routine ultrasound scans. This technology has the potential to revolutionize perioperative fluid management by offering a rapid, non-invasive, and accurate tool for objective volume status assessment, ultimately guiding personalized therapy and improving patient outcomes.",[396,397,398],"Blood Volume Analysis","Ultrasound","Machine Learning","2025-11-13",{"date":401,"type":32},"2025-11-17",{"date":403,"type":32},"2025-10-01",{"date":405,"type":20},"2027-08-31",{"name":38,"class":39},{"id":408,"slug":409,"hasResults":12,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":4,"eligibilityCriteria":413,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":414,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":416,"conditions":417,"keywords":4,"overallStatus":355,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":420,"startDateStruct":422,"completionDateStruct":424,"leadSponsor":426,"locationsCount":4},"100608087","validation-of-whole-body-petct-foundation-model-100608087","NCT07196995","Validation of Whole Body PET\u002FCT Foundation Model","Prospective Multicenter Validation of Whole Body PET\u002FCT Foundation Model for Bone Lesion Detection","Inclusion Criteria:\n\n* With suspicious lesion in the bone or with elevated serum tumor markers or patient insist\n* Over 18 years\n\nExclusion Criteria:\n\n* Active infection at or adjacent to the puncture site\n* Severe coagulation disorders that cannot be corrected\n* Random blood glucose \\> 11.1 mmol\u002FL\n* Refuse for pathological confirmation or follow-up\n* Extremely debilitated patients or those unable to cooperate",{"count":415,"type":20},180,"Prospective multicenter study to validate the diagnostic performance of whole body PET\u002FCT foundation model for bone lesion detection",[418],"Bone Metastases","2025-09-29",{"date":421,"type":32},"2025-10-03",{"date":423,"type":20},"2025-10-16",{"date":425,"type":20},"2026-12-15",{"name":38,"class":39},{"id":428,"slug":429,"hasResults":12,"nctId":430,"briefTitle":431,"officialTitle":431,"acronym":4,"eligibilityCriteria":432,"healthyVolunteers":12,"sex":16,"minAge":433,"maxAge":289,"enrollmentInfo":434,"targetDuration":4,"studyType":21,"phases":436,"briefSummary":437,"conditions":438,"keywords":4,"overallStatus":355,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":446,"locationsCount":4},"100588074","intervention-effects-of-optimized-carbohydrate-diet-in-patients-with-type-2-diabetes-100588074","NCT06936657","Intervention Effects of Optimized Carbohydrate Diet in Patients With Type 2 Diabetes","Inclusion Criteria:\n\n1. Patients diagnosed with type 2 diabetes according to the ADA diagnostic criteria\n2. HbA1c ≥ 7% and \\\u003C 9%\n3. Antidiabetic medication has been stable for at least 3 months before recruitment\n4. Aged 35-70 years\n5. Signed the informed consent form\n\nExclusion Criteria:\n\n1. Treatment with insulin\n2. Treatment with GLP-1 receptor agonists or DPP-4 inhibitors\n3. Occurrence of diabetic ketoacidosis, lactic acidosis, hyperosmolar coma, or recurrent severe hypoglycemia within the past year\n4. Having one or more severe chronic diabetic complications, including advanced diabetic retinopathy, macroalbuminuria (urine albumin-to-creatinine ratio ≥300 mg\u002Fg), or impaired renal function (eGFR ≤60 ml\u002Fmin\u002F1.73 m²)\n5. Presence of cardiovascular events (e.g., myocardial infarction, stent placement, unstable angina, heart failure, cardiac dysfunction) or cerebrovascular diseases (e.g., intracerebral hemorrhage, ischemic stroke) within the past 6 months\n6. Diagnosis of acute or chronic gastrointestinal diseases (e.g., ulcers), hyperthyroidism or hypothyroidism, uncontrolled hypertension, active malignancy not in remission, or other life-threatening diseases\n7. Recent use of antibiotics, probiotics, or prebiotics within the past 3 weeks or need for long-term use\n8. Unstable medication regimen or use of prescription medications affecting metabolism (e.g., thyroid hormones, glucocorticoids)\n9. Pregnancy, breastfeeding, or planning pregnancy\n10. Presence of a pacemaker or metal implants, claustrophobia, or other contraindications to fMRI\n11. Psychiatric disorders impairing cooperation\n12. Expected poor compliance\n13. Current or recent (within 4 weeks prior to study initiation) participation in other clinical trials","35 Years",{"count":435,"type":20},150,[53],"This study is a multi-center, randomized, crossover investigator-initiated trial conducted at Shanghai Sixth People's Hospital and other centers. Each participant will undergo two 12-week dietary intervention phases, separated by a 6-week washout, for a total study duration of 30 weeks. Participants will be randomly assigned in a 1:1 ratio to one of two intervention order: (1) optimized carbohydrate diet-washout-conventional diabetes diet, or (2) conventional diabetes diet-washout-optimized carbohydrate diet. The optimized carbohydrate diet is a modified diet with adjusted carbohydrate composition and proportions, while the conventional diabetes diet adheres to an energy-matched protocol in accordance with diabetes dietary guidelines. The study aims to explore the effects of the optimized carbohydrate diet on blood glucose control and glucose metabolism in patients with type 2 diabetes, and to systematically assess its impact on cognitive function and a range of physiological and psychological indicators (such as depression, anxiety, appetite, sleep, bowel habits and others).",[56],"2025-09-05",{"date":441,"type":32},"2025-09-12",{"date":443,"type":20},"2025-10-20",{"date":445,"type":20},"2027-10-31",{"name":38,"class":39},{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":4,"eligibilityCriteria":453,"healthyVolunteers":208,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":454,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":456,"conditions":457,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":467,"locationsCount":40},"100605868","establishment-and-clinical-application-of-reference-intervals-of-salivary-cortisol-100605868","NCT07168122","Establishment and Clinical Application of Reference Intervals of Salivary Cortisol","Study for Reference Intervals and Optimal Cut-offs for Salivary Cortisol","Healthy Volunteers:\n\nInclusion Criteria:\n\n1. Age ≥ 18 and ≤ 60 years old;\n2. Body mass index (BMI) ≥ 18.5 and ≤ 24.9 kg\\*m\\^-2;\n3. No previous history of chronic diseases such as hyperglycemia, hypertension, dyslipidemia, coronary heart disease and stroke;\n4. Normal glucose regulation, defined as: fasting blood-glucose \\\u003C 5.6 mmol\u002FL, 2-hour blood-glucose after glucose load \\\u003C 7.8 mmol\u002FL, and glycated hemoglobin (HbA1c) \\\u003C 5.7%.\n\nExclusion Criteria:\n\n1. Liver or kidney dysfunction, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or direct bilirubin higher than 1.5 times the upper limit of normal, or serum creatinine \\>115 μmol\u002FL;\n2. Pregnancy or lactation women, or people with cancer or mental illness;\n3. Factors affecting cortisol levels, including hypothalamus-pituitary-adrenal axis disease, autoimmune disease (systemic lupus erythematosus, rheumatoid arthritis, etc.), diagnosed mental disease, Alzheimer's disease, alcoholism (alcohol \\> 60 g\u002Fd for male, \\>40 g\u002Fd for women) and corticosteroid therapy in the past 3 months (females with contraceptives or estrogen);\n4. Factors affecting saliva collection, such as serious oral problems (oral ulcers, gingival bleeding);\n5. Night shift workers, who are awake from 11:00 PM to 7:00 AM;\n6. Acute infection (body temperature ≥ 37.3 ℃ or C-reactive protein \\> 50 mg\u002FL).\n\nCases:\n\nInclusion Criteria:\n\n1. Aged 18 to 80 years old;\n2. Patients with suspected Cushing's syndrome or adrenal insufficiency.\n\nExclusion Criteria:\n\n1. Corticosteroid therapy within the last 6 weeks;\n2. Acute infection;\n3. Severe oral conditions;\n4. Severe liver and kidney dysfunction;\n5. Alcoholism, depression, or other psychiatric disorders.",{"count":455,"type":20},220,"The goal of this observational study is to establish the normal reference intervals of salivary cortisol and optimal cut-offs for Cushing's sydrome and adrenal insufficiency.",[458,459,460],"Healthy Adult","Cushing Syndrome","Adrenal Insufficiency","2025-09-04",{"date":463,"type":32},"2025-09-11",{"date":465,"type":20},"2025-09-01",{"date":66,"type":20},{"name":38,"class":39},{"id":469,"slug":470,"hasResults":12,"nctId":471,"briefTitle":472,"officialTitle":473,"acronym":4,"eligibilityCriteria":474,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":475,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":476,"conditions":477,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":480,"startDateStruct":481,"completionDateStruct":482,"leadSponsor":483,"locationsCount":40},"100604965","salivary-cortisol-and-hypercortisolism-in-type-2-diabetes-100604965","NCT07156370","Salivary Cortisol and Hypercortisolism in Type 2 Diabetes","Study to Explore the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Assess the Correlation Between Salivary Cortisol and Glucose Levels","Inclusion Criteria:\n\n1. Aged between 18 and 80 years.\n2. Meets the definition of difficult to control type 2 diabetes:\n\nHbA1c level between 7.5% and 11.5%, AND Taking 3 or more anti-hyperglycemic drugs. OR Taking insulin and other anti-hyperglycemic drugs. OR Taking 2 or more anti-hyperglycemic drugs AND a.) the presence of 1 or more micro-vascular or macro-vascular complication (retinopathy, diabetic nephropathy and chronic kidney disease, diabetic neuropathy, atherosclerotic heart disease with diabetes); AND\u002FOR b.) concomitant hypertension requiring 2 or more anti-hypertension medications.\n\nExclusion Criteria:\n\n1. Patients with Type 1 diabetes, new-onset diabetes (\\\u003C1 year duration), or other specific types of diabetes.\n2. History of systemic glucocorticoid use within the last 3 months (inhaled or topical agents are not exclusionary).\n3. Pregnant or lactating.\n4. Presence of severe cardiac, hepatic, renal, or other major organ dysfunction.\n5. History of acute diabetic complications, such as diabetic ketoacidosis or hyperosmolar hyperglycemic state, within the last 3 months.\n6. Presence of diseases that significantly affect metabolism, such as malignancy or autoimmune disorders.\n7. Inability to tolerate adhesive tape, severe skin conditions at the sensor placement site, or presence of a psychiatric illness or cognitive impairment that would interfere with study compliance.\n8. A known diagnosis of Cushing's syndrome, or currently receiving treatment with any of the following: mifepristone, metyrapone, osilodrostat, ketoconazole, fluconazole, aminoglutethimide, etomidate, octreotide, larazotide, long-acting octreotide, or pasireotide.\n9. Excessive alcohol consumption (defined as \\>14 units per week for males or \\>7 units per week for females).\n10. Severe, untreated sleep apnea.\n11. Night shift workers (defined as being awake between 11:00 PM and 7:00 AM).\n12. Known allergy or severe reaction to dexamethasone.",{"count":101,"type":20},"The goal of this observational study is to explore the prevalence of hypercortisolism in a population with difficult to control type 2 diabetes despite receiving standard-of-care therapies. Additionally, the study will evaluate the correlation between salivary cortisol levels and glycemic control.",[478,479],"Hypercortisolism","Type 2 Diabetes (T2DM)",{"date":439,"type":32},{"date":465,"type":20},{"date":66,"type":20},{"name":38,"class":39},{"id":485,"slug":486,"hasResults":12,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":4,"eligibilityCriteria":490,"healthyVolunteers":12,"sex":16,"minAge":261,"maxAge":4,"enrollmentInfo":491,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":493,"conditions":494,"keywords":498,"overallStatus":355,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":508,"completionDateStruct":509,"leadSponsor":511,"locationsCount":4},"100604283","relationship-between-mortality-rates-of-fractures-in-different-sites-and-several-factors-in-elderly-patients-100604283","NCT07147504","Relationship Between Mortality Rates of Fractures in Different Sites and Several Factors in Elderly Patients","A Retrospective Study on the Relationship Between Mortality Rates of Fractures in Different Sites and Factors Such as Age, Metabolism, and Nutritional Status in Elderly Patients: A Single-center Retrospective Study","Inclusion Criteria:\n\n* Patients admitted to the National Orthopedic Center of Shanghai Sixth People's Hospital between January 1, 2010, and December 31, 2019;\n* Age ≥ 60 years;\n* Shanghai resident registration;\n* Diagnosed with limb or spinal fractures and receiving surgical treatment at Shanghai Sixth People's Hospital.\n\nExclusion Criteria:\n\n* Multiple fractures;\n* Conservative treatment selected;\n* Incomplete medical records.",{"count":492,"type":20},3000,"Background and Purpose:\n\nAs people age, bones become weaker and break more easily. Older adults (people 60 years and older) who break bones may face serious health problems and have a higher chance of dying compared to younger people. The location of the broken bone, a person's age, and overall health may affect the chances of survival.\n\nThis study will conduct a retrospective analysis of medical records from geriatric patients who underwent surgical intervention for bone fractures at Shanghai Sixth People's Hospital between 2010 and 2019. The primary objective is to identify the key prognostic factors associated with post-operative mortality in this patient cohort.\n\nThe study will retrospectively analyze the medical records of patients who meet all of the following criteria:\n\nAged 60 years or older at the time of fracture diagnosis. Residents of Shanghai. Diagnosed with a fracture of the extremities (upper or lower limbs) or the spine.\n\nUnderwent surgical intervention for the diagnosed fracture.\n\nThe investigators will assess the following variables as potential prognostic factors for post-operative mortality:\n\nFracture Characteristics: The anatomical location of the fracture (e.g., hip, spine, upper extremity, lower extremity).\n\nPatient Demographics: The patient's age at the time of injury. Physiological Status: Indicators of the patient's nutritional and metabolic health.\n\nComorbidities: The presence and severity of pre-existing medical conditions.\n\nHow investigators will do this study:\n\nThis study is designed as a retrospective cohort analysis. Data will be systematically extracted from existing patient medical records. As an observational study, it involves no new interventions or modifications to patient care. The primary endpoint is all-cause mortality, which will be assessed at 1, 3, and 5 years post-operatively to determine long-term survival rates.\n\nInvestigators will group participants by:\n\nThe location of fracture (20 different bone locations); Age (60-65, 66-70, 71-75, 76-80, and over 80 years old); Nutrition and health status.\n\nWhy This Study Matters:\n\nThe results of this study will help doctors better understand which older patients are at higher risk after breaking a bone. This information could help healthcare teams provide better care and potentially save lives by identifying patients who need extra attention and treatment.\n\nStudy Details:\n\nThis study will examine records from approximately 2000 participants; All participants already received their treatment between 2010-2019; No new treatments or procedures will be performed; Participant's privacy will be completely protected; The study will take about 14 months to complete;\n\nThis research will help improve care for older adults who experience bone fractures and may guide treatment decisions for future patients.",[495,496,497],"Fracture Lower Leg","Fracture Dislocation of Upper Limb Joint","Spinal Fractures",[499,500,501,502,503,504],"fracture","Limb fractures","Spinal fractures","Elderly people","the old","Survival rate","2025-08-29",{"date":507,"type":32},"2025-09-08",{"date":465,"type":20},{"date":510,"type":20},"2026-02-28",{"name":38,"class":39},{"id":513,"slug":514,"hasResults":12,"nctId":515,"briefTitle":516,"officialTitle":517,"acronym":518,"eligibilityCriteria":519,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":520,"targetDuration":4,"studyType":21,"phases":522,"briefSummary":523,"conditions":524,"keywords":526,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":537,"locationsCount":40},"100601502","phase-1-safety-and-preliminary-efficacy-of-ievs-injection-in-treating-lateral-epicondylitis-of-humerus-100601502","NCT07111325","Safety and Preliminary Efficacy of iEVs Injection in Treating Lateral Epicondylitis of Humerus","A Clinical Trial Study Evaluating the Safety and Preliminary Efficacy of Human Induced Pluripotent Stem Cell-derived Extracellular Vesicles (iEVs) Injection for the Treatment of Lateral Epicondylitis of the Humerus","iEVs","Inclusion Criteria:\n\n* Diagnosed with lateral epicondylitis by clinical symptom examination and MRI or ultrasound, without obvious tendon tear;\n* Unilateral lateral elbow pain lasting for more than 12 weeks;\n* Pain is provoked by at least 2 of the following methods, with a pain VAS score exceeding 3: maximum grip strength, palpation of the lateral epicondyle of the elbow and surrounding area, resisted dorsiflexion of the wrist or middle finger, or stretching of the forearm extensor muscles under a pain-free grip state;\n* Having received physical therapy or non-steroidal anti-inflammatory drug treatment with poor efficacy;\n* Individuals with independent behavioral capacity, who have signed the informed consent form themselves.\n\nExclusion Criteria:\n\n* Complaints of ipsilateral muscle pain caused by other reasons in the past 6 months;\n* Presence of ipsilateral neurogenic, inflammatory, or systemic joint diseases;\n* A history of previous lateral epicondylitis (LET) surgery in the past 6 months;\n* Subjects deemed unsuitable for participating in the trial due to other conditions, as judged by the researcher;\n* MRI showing that the injury has involved the lateral collateral ligament, with concurrent cartilage damage.",{"count":521,"type":20},24,[23,24],"Evaluate the safety and preliminary efficacy of human induced pluripotent stem cell-derived extracellular vesicle (iEV) injection in the treatment of lateral epicondylitis of the humerus.",[525],"Lateral Epicondylitis",[527,528,529,530],"lateral epicondylitis","tennis elbow","induced pluripotent stem cell","extracellularvesicles","2025-08-07",{"date":533,"type":32},"2025-08-08",{"date":535,"type":32},"2023-07-01",{"date":325,"type":20},{"name":38,"class":39},{"id":539,"slug":540,"hasResults":12,"nctId":541,"briefTitle":542,"officialTitle":542,"acronym":4,"eligibilityCriteria":543,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":544,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":546,"conditions":547,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":555,"locationsCount":40},"100582282","development-and-validation-of-a-digital-twin-based-clinical-research-system-x-town-stage-i-100582282","NCT06861283","Development and Validation of a Digital Twin-based Clinical Research System (X Town Stage I)","Inclusion Criteria:\n\n1. Age≥18 years old\n2. Receiving care at a community health service centre\n3. Able to understand and comply with the study procedures\n4. Agrees to participate in the study and signs the informed consent form\n\nExclusion Criteria:\n\n1. Patients with severe mental illness\n2. Patients expected to be unable to complete follow-ups",{"count":545,"type":20},1500,"Chronic diseases, characterized by their prolonged duration and slow progression, have emerged as predominant contributors to global morbidity and mortality. The investigators have developed a digital twin-based clinical research system (termed X Town) for chronic diseases, to predict clinical outcomes under various interventions. In this study, the investigators aim to evaluate the reliability of the developed digital twin-based clinical research system in predicting short-term clinical outcomes via virtual and real-world clinical studies.",[548],"Chronic Disease","2025-05-14",{"date":551,"type":32},"2025-05-15",{"date":553,"type":32},"2025-04-13",{"date":223,"type":20},{"name":38,"class":39},{"id":557,"slug":558,"hasResults":12,"nctId":559,"briefTitle":560,"officialTitle":561,"acronym":4,"eligibilityCriteria":562,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":563,"targetDuration":77,"studyType":78,"phases":4,"briefSummary":564,"conditions":565,"keywords":566,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":572,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":578,"locationsCount":40},"100480213","clinical-and-molecular-biological-data-collection-and-analysis-in-patients-with-tbi-100480213","NCT05533060","Clinical and Molecular Biological Data Collection and Analysis in Patients With TBI","Clinical and Molecular Biological Data Collection and Analysis in Patients With Traumatic Brain Injury (TBI)","Inclusion Criteria:\n\n* CT\u002FMRI confirmed TBI;\n* The time from onset to the emergency room (ER ) within 12h;\n* The systolic pressure (SBP) ≥ 90 mmHg;\n* Patients willing to participate in this study with signed informed consent.\n\nExclusion Criteria:\n\n* Patients who are not suitable for surgery (GCS score 3 points, dilated and fixed bilateral pupils, pregnant women, etc.);\n* Pre-injury life expectancy ≤ 1 year (malignant tumor);\n* Previous history of acute myocardial infarction, abnormal immune function, and blood-related diseases;\n* without informed consent.",{"count":124,"type":20},"Clinical evaluation is crucial in the clinical diagnosis, treatment, and prognosis prediction in patients with traumatic brain injury (TBI). However, the existing evaluation systems are not perfect, because many factors are not taken into account, for example, there is a lack of molecular diagnostic criteria for evaluating patients with TBI. We attempt to collect the patient's clinical data and combine it with neuroimaging, as well as molecular biomarkers generated by single-cell sequencing to assess their neurological status and outcome. The clinical and molecular data collection and analysis will be helpful to evaluate the patient's neurological condition and predict the patient's outcome more accurately.",[213],[567,568,569,570],"Traumatic brain injury","Molecular biomarkers","Single-cell sequencing","High-throughput sequencing","2025-05-03",{"date":573,"type":32},"2025-05-06",{"date":575,"type":32},"2022-09-01",{"date":577,"type":20},"2027-12-30",{"name":38,"class":39},{"id":580,"slug":581,"hasResults":12,"nctId":582,"briefTitle":583,"officialTitle":583,"acronym":4,"eligibilityCriteria":584,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":585,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":587,"conditions":588,"keywords":4,"overallStatus":355,"whyStopped":4,"lastUpdateSubmitDate":591,"lastUpdatePostDateStruct":592,"startDateStruct":594,"completionDateStruct":596,"leadSponsor":598,"locationsCount":4},"100589980","ai-assisted-quality-control-study-of-multimodal-data-in-the-epidemiological-survey-of-shanghai-nicheng-cohort-study-100589980","NCT06961461","AI-assisted Quality Control Study of Multimodal Data in the Epidemiological Survey of Shanghai Nicheng Cohort Study","Inclusion Criteria:\n\n1. Be proficient in using computers;\n2. The person responsible for questionnaire quality control needs to have good dialect recognition ability;\n3. Have a basic understanding or high acceptance of AI-assisted tools, and be able to adapt to the learning and application of new technologies\n4. Be able to participate in the research throughout the process, abide by the research process, receive training, and be willing to complete quality control tasks as required.\n\nExclusion Criteria:\n\n1. The person responsible for questionnaire quality control cannot understand or recognize Shanghai Nanhui dialect proficiently;\n2. Unfamiliar with AI-assisted tools and difficult to accept technical operations;\n3. Unable to participate in the research, receive training or complete the specified tasks due to other work or academic reasons;",{"count":586,"type":20},900,"This study is based on the Nicheng Cohort study. This study intends to analyze whether AI assistance can effectively improve the efficiency and accuracy of quality control of data collected in large-scale epidemiological surveys based on traditional quality control processes.",[589,590],"Quality Control","Cohort Studies","2025-04-29",{"date":593,"type":32},"2025-05-08",{"date":595,"type":20},"2025-05-01",{"date":597,"type":20},"2025-08-15",{"name":38,"class":39},""]